ImmuCell Corporation (NasdaqCM: ICCC)
Health Care · Biotechnology · US
$9.84
-2.19% today · +65.1% 1Y
ImmuCell Corporation (NasdaqCM: ICCC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $91.37M and employs 73 people.
Over the last twelve months the share price has gained 65.1%, trading between 4.52 and 12.10.
Tweenvest scores ImmuCell Corporation across four factors: quality 67/100, value 34/100, growth 52/100. Its strongest factor is quality.
ICCC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $91.37M
- Revenue (TTM)
- $30.68M
- P/E
- 134.90
- EPS
- 0.07
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- $12.10
- 52-week low
- $4.52
- Avg volume (3M)
- —
- Shares outstanding
- 9.08M
- Employees
- 73
- Next earnings
- —
About ImmuCell Corporation
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
- ISIN
- US4525253062
- Founded
- 1982
- Listed since
- May 5, 1987
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.